Clinical Trial Update: Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis

View source ↗

Summary

The document reports expanded access for Bezuclastinib to patients with nonadvanced or advanced systemic mastocytosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Systemic Mastocytosis
• Indolent Systemic Mastocytosis
• Systemic Mastocytosis

Drugs mentioned

• Bezuclastinib (bezuclastinib)

Snippet

Sponsor: Cogent Biosciences, Inc. | Conditions: Systemic Mastocytoses, Indolent, Systemic Mastocytoses, Aggressive | Status: AVAILABLE